Previously, I've written posts (no. 1 & no. 2) regarding Judge Sweet's ruling in the Myriad gene patent case for BRCA 1&2. Myriad and its backers need to file their appeal by June 18th - 60 days after the decision - which they will do.
Today the Kevin Noonan, in his Patent Docs blog, did an excellent job of reviewing the popular and not so popular opinion coming from all walks of life following the decision. I couldn't begin to duplicate this post - so I won't try. I've just passed it on for your reading pleasure.
The blog provides an extensive list of references if you care to read in even more depth.
Posted by Bruce Lehr June 9th 2010.
A reminder from the WSJ Health blog (Aug 31st) as to why this issue may have real importance to women's health far beyond the arguments in the court room.
http://blogs.wsj.com/health/2010/08/31/study-suggests-importance-of-screening-for-brca-gene-mutations/
Posted by: bigredbruce | 08/31/2010 at 03:37 PM
The BioJobBlog recently noted that the FDA will crack down on some suppliers of genetic testing services - is this another reaction to the Sweet ruling - effectively is the FDA recognizing public resistance to genetic test monopolies?
http://www.biojobblog.com/2010/06/articles/biobusiness/fda-begins-reining-in-genetic-testing-companies-its-about-time/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+BioJobBlog+%28Bio+Job+Blog%29&utm_content=Google+Reader
Posted by: bigredbruce | 06/15/2010 at 06:58 PM
Lest we forget that a Company's financial health and people's jobs are related - I thought I'd throw in this downstream effect at Myriad from the Sweet ruling.
http://www.thepharmaletter.com/file/95689/myriad-pharma-to-focus-on-oncology-portfolio-cutting-staff-to-conserve-financial-resources.html
Posted by: bigredbruce | 06/10/2010 at 07:23 AM